Zhitong Finance App News, Junshi Biotech (688180.SH) announced that the company received a notice from the US Food and Drug Administration (“FDA”), and the clinical trial application for EGFR/HER3 bispecific antibody conjugate drug (code: JS212) for the treatment of advanced solid tumors was approved by the FDA.

Zhitong Finance App News, Junshi Biotech (688180.SH) announced that the company received a notice from the US Food and Drug Administration (“FDA”), and the clinical trial application for EGFR/HER3 bispecific antibody conjugate drug (code: JS212) for the treatment of advanced solid tumors was approved by the FDA.